46 completed, 7 terminated, 4 recruiting, 3 unknown. 14 Phase 4, 13 Not applicable, 12 Phase 2, 9 Phase 1, 5 Early Phase 1.
Follow regadenoson: new trials by email Literature Review of regadenoson trials Research Report on regadenoson
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET [13N]NH3, Lexiscan, Positron emission tomography - Sickle Cell Disease | Phase 2 | Recruiting | St. Jude Children's Research Hospital | 40 | 2023-10-10 | 2026-05-06 |
| The MATCH Investigation: CT Myocardial Perfusion and CT-FFR vs PET MPI PET-MPI Protocol, CT-MPI, Coronary CT angiography (CCTA) for CT-FFR calculation - Coronary Artery Disease | Not applicable | Completed | Emory University | 20 | 2021-06-16 | 2026-01-06 |
| A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients Regadenoson - Myocardial Ischemia, Coronary Artery Disease | Phase 1 / Phase 2 | Recruiting | GE Healthcare | 54 | 2021-05-20 | 2026-05-06 |
| Treat COVID-19 Patients With Regadenoson Regadenoson, Placebo Control - COVID-19, Lung Inflammation | Phase 1 / Phase 2 | Completed | University of Maryland, Baltimore | 5 | 2021-05-06 | 2025-03-20 |
| Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System Regadenoson, Placebo - Lung Transplant | Early Phase 1 | Completed | University of Maryland, Baltimore | 47 | 2020-06-22 | 2024-08-05 |
| Determining Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas Regadenoson 0.05mg, Regadensoson 0.1mg, Regadensoson 0.2mg - High Grade Glioma, Anaplastic Astrocytoma | Phase 1 | Terminated | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 7 | 2019-12-06 | 2023-10-06 |
| Allograft Dysfunction in Heart Transplant Regadenoson - Heart Transplant Failure and Rejection | Phase 4 | Recruiting | Paul Kim | 376 | 2019-10-01 | 2026-05-01 |
| Arm Exercise Versus Pharmacologic Stress Testing for Clinical Outcome Regadenoson myocardial perfusion imaging stress test, Arm exercise electrocardiographic stress test, Treadmill electrocardiographic stress test - Veterans Referred to the St. Louis VAMC Stress Tes | Terminated | VA Office of Research and Development | 133 | 2018-07-01 | 2022-02-17 | |
| Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer Adenosine, Magnetic Resonance Imaging, Regadenoson - Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8 | Completed | Wake Forest University Health Sciences | 25 | 2018-06-21 | 2026-01-29 | |
| Whole-Heart Myocardial Blood Flow Quantification Using MRI Myocardial Perfusion Cardiac MRI., Contrast, Pharmacologic Stress Agent - Coronary Artery Disease, Coronary Microvascular Disease | Unknown | Cedars-Sinai Medical Center | 160 | 2018-03-01 | 2023-02-08 | |
| A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI SAR407899, Placebo, Adenosine - Microvascular Coronary Artery Disease | Phase 2 | Terminated | Sanofi | 10 | 2017-10-12 | 2022-03-24 |
| Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve Regadenoson, Adenosine - Hypertrophic Cardiomyopathy, Non-ischemic Dilated Cardiomyopathy | Phase 4 | Terminated | Duke University | 31 | 2017-09-05 | 2020-09-16 |
| Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT Cardiac Perfusion Rest/Stress Digital PET/CT, N-13 ammonia, Regadenoson - Coronary Artery Disease | Completed | Stanford University | 15 | 2017-03-29 | 2021-10-26 | |
| The Effect of A2A Adrenoceptor Stimulation on the Diameter of Retinal Arterioles During Hypoxia in Vivo Hypoxia, Regadenoson - Retinal Artery Occlusion | Phase 2 | Unknown | University of Aarhus | 20 | 2017-03-22 | 2017-03-28 |
| New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF) Adenosine, Regadenoson, O-15 labeled radioactive water - MRI Scans | Early Phase 1 | Recruiting | University of Utah | 100 | 2017-03-03 | 2026-07-07 |
| Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System Lexiscan - Cardiovascular Diseases, Coronary Artery Disease | Phase 2 | Completed | Medical University of South Carolina | 24 | 2016-02-09 | 2019-08-09 |
| Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements Regadenoson - Coronary Artery Disease | Completed | University of Illinois at Chicago | 183 | 2016-02-01 | 2019-10-24 | |
| Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction Regadenoson, Gadolinium, Cardiac MRI - Heart Transplant, Acute Graft Rejection | Phase 4 | Completed | Paul Kim | 14 | 2015-11-01 | 2017-08-22 |
| Myocardial Perfusion, Oxidative Metabolism, and Fibrosis in HFpEF regadenoson - Heart Failure, Diastolic, Diastolic Heart Failure | Phase 4 | Completed | Marvin W. Kronenberg, M.D. | 55 | 2015-11-01 | 2021-02-02 |
| Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration Regadenoson, Temozolomide, Microdialysis catheter - Blood Brain Barrier Defect | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 6 | 2015-02-01 | 2018-11-20 |
Showing 20 of 63. Sign in to see all of them.
Coronary Artery Disease (33) · Myocardial Ischemia (8) · Anemia, Sickle Cell (4) · Coronary Disease (3) · Ischemia (3) · Asthma (2) · Cardiovascular Diseases (2) · Heart Diseases (2) · Pulmonary Disease, Chronic Obstructive (2) · Angina Pectoris (1) · Astrocytoma (1) · Atherosclerosis (1) · Atrial Fibrillation (1) · COVID-19 (1) · Cardiomyopathy, Hypertrophic (1)
Astellas Pharma Inc (4) · University of Utah (4) · Gilead Sciences (3) · University of Chicago (3) · University of Maryland, Baltimore (3) · Astellas Pharma Global Development, Inc. (2) · Cedars-Sinai Medical Center (2) · Dana-Farber Cancer Institute (2) · Emory University (2) · Mayo Clinic (2) · Paul Kim (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · University of Nebraska (2) · Wake Forest University Health Sciences (2) · Washington University School of Medicine (2)
United States (60) · Denmark (2) · United Kingdom (2) · Argentina (1) · France (1) · Greece (1) · Italy (1) · Netherlands (1) · Peru (1) · Puerto Rico (1) · South Korea (1) · Sweden (1)
David Nathan, MD (2) · Edward DiBella, Ph.D. (2) · Thomas R Porter, MD (2) · Timothy M Bateman, MD (2) · Amit Patel, M.D. (1) · Ananda Basu, MBBS, M.D. (1) · Brent Wilson, MD (1) · Brett E Fenster, MD (1) · Carlo De Cecco, MD, PhD (1) · Christine L Lau, MD, MBA (1) · Christine Lau, MD (1)
PMID 11693758, PMID 11943259, PMID 16353442, PMID 16890123, PMID 17194875, PMID 17826318, PMID 18551063, PMID 19284612, PMID 20413602, PMID 20643330, PMID 21082298, PMID 21555100, PMID 21962016, PMID 21968545, PMID 22484721, PMID 23180239, PMID 23272658, PMID 23377438, PMID 23671819, PMID 24314823, PMID 24331202, PMID 24355800, PMID 24457279, PMID 26242981, PMID 26607361, PMID 28174191, PMID 28224449, PMID 28528431, PMID 29296811, PMID 3308166, PMID 34335296, PMID 40225909, PMID 9498540
1RC2HL101367-01 (1), 2016 (1), P30CA012197 (1), P50HL110790 (1), R01EB002623 (1), R01HL124649 (1), R01HL128492 (1), R01HL135328 (1), UM1CA137443 (1)